Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention - A Lescol Intervention Prevention Study (LIPS) substudy

American Heart Journal

Volumn 149, Issue 2, 2005, Pages 329-335

  Arampatzis, Chourmouzios A ^a   Goedhart, Dick ^b   Serruys, Patrick W ^a   Saia, Francesco ^a   Lemos, Pedro A ^a   De Feyter, Pim ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 14844337512     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.067     Document Type: Article

References (36)

1. M. Laakso Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes Prim. Care 26 1999 829 839
2. S.M. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339 1998 229 234
3. I. Saito, A.R. Folsom, and F.L. Brancati Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study Ann. Intern. Med. 133 2000 81 91
4. S. Elezi, A. Kastrati, and J. Pache Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement J. Am. Coll. Cardiol. 32 1998 1866 1873
5. B. Stein, W.S. Weintraub, and S.P. Gebhart Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty Circulation 91 1995 979 989
6. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 96 1997 1761 1769
7. A. Abizaid, M.A. Costa, and M. Centemero Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial Circulation 104 2001 533 538
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N. Engl. J. Med. 339 1998 1349 1357
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
10. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
11. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N. Engl. J. Med. 335 1996 1001 1009
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
13. P.W. Serruys, P. de Feyter, and C. Macaya Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
14. P.W. Serruys, P.J. De Feyter, and R. Benghozi The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease Int. J. Cardiovasc. Intervent. 4 2001 165 172
15. F.M. Sacks, A.M. Tonkin, and J. Shepherd Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
16. K.E. Kip, D.P. Faxon, and K.M. Detre Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry Circulation 94 1996 1818 1825
17. J.P. Carrozza Jr., R.E. Kuntz, and R.F. Fishman Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus Ann. Intern. Med. 118 1993 344 349
18. R. Kornowski, G.S. Mintz, and K.M. Kent Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study Circulation 95 1997 1366 1369
19. P.R. Moreno, J.T. Fallon, and A.M. Murcia Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients J. Am. Coll. Cardiol. 34 1999 1045 1049
20. G. Davi, I. Catalano, and M. Averna Thromboxane biosynthesis and platelet function in type II diabetes mellitus N. Engl. J. Med. 322 1990 1769 1774
21. E. Van Belle, M. Perie, and D. Braune Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients J. Am. Coll. Cardiol. 40 2002 410 417
22. E.J. Topol, D.B. Mark, and A.M. Lincoff Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting Lancet 354 1999 2019 2024
23. L. Gruberg, R. Waksman, and A.E. Ajani The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus J. Am. Coll. Cardiol. 39 2002 1930 1936
24. D. Aronson, Z. Bloomgarden, and E.J. Rayfield Potential mechanisms promoting restenosis in diabetic patients J. Am. Coll. Cardiol. 27 1996 528 535
25. T. Kanzaki, M. Shinomiya, and S. Ueda Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF β-receptor overexpression of aortic media Eur. J. Clin. Invest. 24 1994 377 381
26. K.E. Bornfeldt, E.W. Raines, and T. Nakano Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation J. Clin. Invest. 93 1994 1266 1274
27. S.M. Haffner, C.M. Alexander, and T.J. Cook Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study Arch. Intern. Med. 159 1999 2661 2667
28. M.E. Bertrand, E.P. McFadden, and J.C. Fruchart Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty J. Am. Coll. Cardiol. 30 1997 863 869
29. W.S. Weintraub, S.J. Boccuzzi, and J.L. Klein Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group N. Engl. J. Med. 331 1994 1331 1337
30. P.W. Serruys, D.P. Foley, and G. Jackson A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial Eur. Heart J. 20 1999 58 69
31. T.J. Anderson, I.T. Meredith, and A.C. Yeung The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion N. Engl. J. Med. 332 1995 488 493
32. H.W. Eichstadt, H. Eskotter, and I. Hoffman Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease Am. J. Cardiol. 76 1995 122A 125A
33. G. Dangas, J.J. Badimon, and D.A. Smith Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile J. Am. Coll. Cardiol. 33 1999 1294 1304
34. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
35. A. Corsini Fluvastatin: effects beyond cholesterol lowering J. Cardiovasc. Pharmacol. Ther. 5 2000 161 175
36. M. Degertekin, P.W. Serruys, and D.P. Foley Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up Circulation 106 2002 1610 1613